Pfenex Chief Medical Officer Hubert Chen to Share Clinical Expertise at Biosimilars & Biobetters Congress

London, UK – April 15, 2016

Who:   Pfenex Chief Medical Officer Hubert C. Chen, M.D.

What:  Case Study Presentation at 4th Annual Biosimilars & Biobetters Congress

When: Tuesday, April 19, 2016 at 16.00 – 16.30 GMT

Where: Novotel London West Hotel, 1 Shortlands, London, W6 8DR, United Kingdom

Why:   Dr. Hubert Chen, M.D., Chief Medical Officer of biosimilars company Pfenex, will present a case-study example illustrating best practices in clinical development for a biosimilar candidate to Interferon beta-1b for the treatment of multiple sclerosis.

About Pfenex

Pfenex Inc. (NYSE: PFNX) is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value, and difficult-to-manufacture, proteins. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis® (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology® platform to build a pipeline of product candidates under development including other biosimilars, as well as vaccines, generics, and next-generation biologics. For additional information, visit Pfenex.com and connect with us on Twitter @Pfenex.

###

Note: All trademarks mentioned herein are property of their respective owners.

Media contact: Michelle Ragsdale, Pfenex | Direct (858) 352-4391 | mragsdale@pfenex.com